Ginkgo Bioworks (DNA) vs Fennec Pharmaceuticals (FENC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Fennec Pharmaceuticals (FENC) has outperformed Ginkgo Bioworks (DNA) over the past year, gaining 66.1% versus a loss of 8.7%. Over five years, FENC leads with a +35.8% price change compared with -98.5% for DNA. Ginkgo Bioworks is the larger company by market cap ($483.5 million vs $462.1 million), about 1.0 times the size, while Fennec Pharmaceuticals is growing revenue faster (-6.1% vs -25.1%).
Fennec Pharmaceuticals converts more of its revenue into profit, with a net margin of -21.8% versus -183.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DNA | FENC |
|---|---|---|
| Share price | $7.46 | $13.09 |
| Market cap | $483.54M | $462.14M |
| 1-day change | -9.02% | -2.68% |
| YTD return | -10.23% | +70.00% |
| 1-year return | -8.69% | +66.12% |
| 5-year return | -98.45% | +35.79% |
| P/E ratio (TTM) | — | 436.33 |
| Forward P/E | — | 12.47 |
| EPS (TTM) | $-4.24 | $0.03 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $170.16M | $44.64M |
| Revenue growth (YoY) | -25.06% | -6.09% |
| Net income (latest FY) | $-312.76M | $-9.74M |
| Operating margin | -185.29% | -14.07% |
| Net margin | -183.81% | -21.82% |
| 52-week high | $18.22 | $13.85 |
| 52-week low | $5.37 | $5.65 |
| Distance from 52-week high | -59.06% | -5.49% |
| Analyst consensus | underperform | strong_buy |
| Avg. price target upside | +7.24% | +34.45% |
| Average volume | 2.53M | 220.87K |
| Shares outstanding | 53.94M | 35.31M |
| Employees | 485 | 35 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FENC has outperformed DNA by 74.8 percentage points over the past year.
- Fennec Pharmaceuticals is more profitable, keeping -21.8 cents of every revenue dollar as net income versus -183.8 cents for Ginkgo Bioworks.
- Fennec Pharmaceuticals grew revenue faster in its latest fiscal year (-6.09% vs -25.06%).
About Ginkgo Bioworks
DNA stock →Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 485 employees
About Fennec Pharmaceuticals
FENC stock →Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 35 employees
DNA vs FENC FAQ
Which is bigger, Ginkgo Bioworks or Fennec Pharmaceuticals?
Ginkgo Bioworks (DNA) is larger, with a market capitalization of $483.54M compared with $462.14M for Fennec Pharmaceuticals (FENC).
Which stock has performed better over the past year, DNA or FENC?
FENC returned +66.12% over the past 12 months, compared with -8.69% for DNA (price return, excluding dividends). Past performance does not predict future results.
Are Ginkgo Bioworks and Fennec Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.